Gurmohan Syali, MD
Medical Oncology · E Setauket, NYNPI 1932195138
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Gilead at 34.3% of the total. 2025 is the largest year on record at $128, 3.0 times the $42 reported in 2019. That places this record below the midpoint for medical oncology clinicians in NY, where the typical reported total is $4,912.
Across 16 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$103
- Novartis$88
- Menarini Silicon Biosystems, Inc.$47
- Sanofi$36
- Epizyme, Inc.$15
- Kyowa Kirin, Inc.$11
What the payments were for
- Food & beverage$299100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 6 | $103 |
| Novartis | 5 | $88 |
| Menarini Silicon Biosystems, Inc. | 2 | $47 |
| Sanofi | 1 | $36 |
| Epizyme, Inc. | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $11 |
How this compares
$299 in reported general payments places this provider in the 25th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 72 | $1,070,016 |
| AranespDarbepoetin Alfa In Polysorbat | 166 | $606,393 |
| ImbruvicaIbrutinib | 33 | $519,882 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 57 | $437,585 |
| RevlimidLenalidomide | 21 | $401,976 |
| Somatuline DepotLanreotide Acetate | 44 | $390,095 |
| CalquenceAcalabrutinib Maleate | 25 | $351,936 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 31 | $327,184 |
| ErbituxCetuximab | 21 | $307,026 |
| XgevaDenosumab | 83 | $258,652 |
| Neulasta OnproPegfilgrastim | 43 | $255,185 |
| XtandiEnzalutamide | 13 | $180,906 |
| NeulastaPegfilgrastim | 21 | $158,634 |
| NplateRomiplostim | 14 | $154,626 |
| AkynzeoFosnetupitant/Palonosetron | 107 | $124,838 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in E Setauket
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Maria TheodoulouAlbany$1.1M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Anthony MatoIthaca$909K
- Ehsan MalekBuffalo$826K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
- Komal JhaveriNew York$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.